EPHB2 and metastatic malignant neoplasm: First, systemic therapy might be a confounding factor in assessing the prognostic value of EphB2. It is possible that this is in line with the paradoxical impact of chemotherapy, which ensures therapeutic efficacy regarding the primary tumor, despite eventually favoring survival and dissemination of metastatic cancer cells [43,44].